Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price dropped 1% during trading on Friday . The stock traded as low as $7.21 and last traded at $7.28. Approximately 1,143,010 shares were traded during trading, a decline of 82% from the average daily volume of 6,209,305 shares. The stock had previously closed at $7.35.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th.

Recursion Pharmaceuticals Price Performance

The company has a market capitalization of $1.72 billion, a PE ratio of -4.55 and a beta of 0.83. The firm has a 50-day moving average of $8.81 and a 200 day moving average of $9.88.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.04. The business had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The business’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period last year, the firm posted ($0.34) earnings per share. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $3,860,644.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total transaction of $43,260.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $3,860,644.97. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total value of $87,684.02. Following the transaction, the director now directly owns 7,229,861 shares in the company, valued at $55,380,735.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 207,359 shares of company stock valued at $1,704,435. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. National Bank of Canada FI raised its stake in Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares during the period. Wedmont Private Capital raised its stake in Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares during the period. Benjamin F. Edwards & Company Inc. bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at approximately $26,000. Arizona State Retirement System raised its stake in Recursion Pharmaceuticals by 8.5% during the 4th quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock valued at $394,000 after purchasing an additional 3,125 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in Recursion Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 16,359 shares of the company’s stock valued at $161,000 after purchasing an additional 4,148 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.